Mustang Bio announces MB-107 lentiviral gene therapy granted RMAT designation
Mustang Bio and St. Jude Children’s Research Hospital announced that MB-107, a lentiviral gene therapy for treatment of X-linked severe combined immunodeficiency has been granted the Regenerative Medicine Advanced Therapy designation by the FDA. August 22, 2019